Meeting
2022 ASCO Annual Meeting
Density patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057.
Authors
Germán Corredor
Case Western Reserve University, Cleveland, OH
Germán Corredor , Ruiwen Ding , Prateek Prasanna , Cristian Barrera , Paula Toro , Vidya Sankar Viswanathan , Philipp Zens , Sabina Berezowska , Vipul Baxi , David Balli , Merzu Belete , Vamsidhar Velcheti , Kurt A. Schalper , Anant Madabhushi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2662)
DOI
10.1200/JCO.2022.40.16_suppl.2662
Abstract #
2662
Poster Bd #
316
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
The impact of PD-L1 on survival and values of nivolumab, atezolizumab, and pembrolizumab compared with docetaxel in second-line non-small cell lung cancer.
First Author: Helmy M. Guirgis
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
First Author: Sun Young Jeong
First Author: Toni K. Choueiri